Conference Coverage

Reduced intensity conditioning doesn’t protect fertility


 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS


Patients received their transplants for a variety of malignant and nonmalignant conditions.

“We saw relatively normal gonadotropins after both reduced intensity and myeloablative conditioning in males,” Dr. Oquendo del Toro said. Of the MAC group, 4 of 15 (27%) had elevated follicle stimulating hormone levels, as did 2 of 17 (12%) of the RIC group. Elevated luteinizing hormone levels were seen in 2 of 15 (13%) of the MAC group and 1 of 17 (6%) of the RIC group. Four patients in each group had abnormally low testosterone levels.

However, when the investigators looked at inhibin B levels in males, they found abnormally low levels in 9 of 15 (60%) of those who received MAC, and in 6 of 15 (40%) of those who received RIC. These results meshed with the severely abnormal semen analyses investigators found from those participants for whom a sample was available, Dr. Oquendo del Toro said.

For females, estradiol levels were significantly lower for those who had received MAC, with 7 of 11 (64%) of that group having abnormally low estradiol levels. The levels approached 0 pg/mL for many, said Dr. Oquendo del Toro. None of the eight patients who had received RIC had abnormally low estradiol levels (P = .0008).

Pages

Recommended Reading

Nonmyeloablative conditioning gets a radiation boost for severe hemoglobinopathies
MDedge Hematology and Oncology
KD025 shows promise for steroid-dependent cGVHD
MDedge Hematology and Oncology
CAR T before transplant yields durable remission in B-cell malignancies
MDedge Hematology and Oncology
Xenon imaging could detect lung involvement after HSCT
MDedge Hematology and Oncology
Low microbiota diversity linked to poor survival after transplant
MDedge Hematology and Oncology
Ibrutinib preserves immune memory while fighting cGVHD
MDedge Hematology and Oncology
Posttransplant cyclophosphamide helped reduce GVHD rates
MDedge Hematology and Oncology
High engraftment with new umbilical transplant technique
MDedge Hematology and Oncology
Study: Stick with TMP-SMX for posttransplant PJP prophylaxis
MDedge Hematology and Oncology
Coming soon: CAR T-cell approvals in multiple myeloma
MDedge Hematology and Oncology